A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: ridaforolimus + dalotuzumab|DRUG: exemestane|DRUG: ridaforolimus|DRUG: dalotuzumab
Sponsor: Merck Sharp & Dohme LLC